# reload+after+2024-01-20 14:46:03.713696
address1§1 Casper Street
city§Danbury
state§CT
zip§06810
country§United States
phone§818 661 5000
website§https://www.mannkindcorp.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
fullTimeEmployees§391
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Michael E. Castagna Pharm.D.', 'age': 46, 'title': 'CEO & Director', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 1258658, 'exercisedValue': 0, 'unexercisedValue': 5418472}, {'maxAge': 1, 'name': 'Mr. Steven B. Binder', 'age': 60, 'title': 'Chief Financial Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 800204, 'exercisedValue': 0, 'unexercisedValue': 1889249}, {'maxAge': 1, 'name': 'Dr. David B. Thomson', 'age': 56, 'title': 'Executive VP, General Counsel & Secretary', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 798535, 'exercisedValue': 0, 'unexercisedValue': 1923614}, {'maxAge': 1, 'name': 'Dr. Stuart A. Tross Ph.D.', 'age': 56, 'title': 'Executive VP and Chief People & Workplace Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 678404, 'exercisedValue': 0, 'unexercisedValue': 2072168}, {'maxAge': 1, 'name': 'Mr. Sanjay  Singh M.B.A.', 'age': 57, 'title': 'Executive Vice President of Technical Operations', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 364529, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lauren M. Sabella', 'age': 62, 'title': 'Executive VP & COO', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Rosabel Realica Alinaya', 'age': 62, 'title': 'VP of Investor Relations & Treasury', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 402256, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John F. Bedard', 'age': 73, 'title': 'Senior Vice President of Worldwide Regulatory Affairs', 'yearBorn': 1950, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James Patrick McCauley Jr., J.D., M.B.A.', 'age': 57, 'title': 'Chief Commercial Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 614059, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Matthew H. Nguyen PharmD', 'age': 53, 'title': 'Senior Vice President of Endocrine Business Unit', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§3
compensationRisk§3
shareHolderRightsRisk§4
overallRisk§3
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.306
priceToSalesTrailing12Months§5.557965
currency§USD
dateShortInterest§1702598400
forwardEps§0.09
pegRatio§-2.68
exchange§NGM
quoteType§EQUITY
shortName§MannKind Corporation
longName§MannKind Corporation
firstTradeDateEpochUtc§1091021400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§44f4c2b0-ea57-32ef-9865-46daf7cd45e6
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§5.0
targetMeanPrice§6.92
targetMedianPrice§6.75
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§1.781
grossMargins§0.65546
ebitdaMargins§-0.01508
trailingPegRatio§None
